£50 million malaria project announced for Nigeria
This article was originally published in Scrip
Executive Summary
A new £50 million project to tackle malaria in Nigeria has been announced by the UK Department for International Development (DFID). The project will provide up to four million mosquito bed nets and 10 million antimalarial drug treatments, alongside additional health measures, and will target pregnant mothers, babies and children. International Development Minister Gillian Merron welcomed the project, saying it could directly prevent around 150,000 deaths and, by tying in with other resources, had the potential to prevent up to a million. The investment will also support Nigeria's five year National Malaria Control Programme (NMCP), along with extra funding from the Nigerian Government, the Global Fund and the World Bank, among other donors.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).